After an endocrinologist in Walnut Creek, California, diagnosed a middle-aged male patient with hypertension, she put him on a regimen of Diovan, a medication that lowers blood pressure, and sent him home with supplies: a waterproof stick-on patch and a bottle of microchips.
The patch adhered like a Band-Aid to the patient’s abdomen and measured body temperature and other vital signs. The microchips, which were stuck to the outside of otherwise ordinary-looking pills, sent a signal to the patch when stomach fluids activated them, indicating that they’d been swallowed. Then, whenever the patient got within range of his smart phone, data collected by the patch was uploaded to the Internet over a Bluetooth connection. The data was aggregated and fed into a user interface, and with the patient’s permission, the results were made available to the doctor.
The physician saw that her patient was taking his Diovan with near-perfect consistency, every morning at almost the same time. Until, suddenly, he stopped. When she discovered that, she gave him a call. “Is anything wrong?” she asked.
“It’s funny you should ask that,” the patient said. “My dog just died.”
Andrew Thompson is cofounder and CEO of Proteus Biomedical, the startup behind the smart-pill system, and his voice speeds up with excitement as he relates the incident and its implications. The dog’s death represents “a significant change in someone’s ability to manage their disease because of a completely unrelated life event that’s causing stress,” Thompson says. “It shows that people aren’t robots. They need help. They need tools.”
Such tools could have a major impact on health care, helping people avoid the need for pricey hospital stays. They could help people with chronic diseases take control of their health and share their vital signs with their physicians in real time. The result could be a gradual decrease in medical costs. Eric Topol, director of the Scripps Translational Science Institute in La Jolla, California, believes that extending the reach of the primary-care physician is the key to cutting costs, and he thinks wireless technology is the best way to do it. “It’s the beginning of an era of remote monitoring,” says Topol. “What do we need hospital beds for except for the highest-acuity intensive-care setting?”
In short, these technologies could help avert a looming disaster. Hospitals have limited space and cash, and primary-care physicians are stretched to the limit at a time when the wave of aging baby boomers is poised to swamp the health-care system. The best solution is to prevent as many hospital visits as possible. Says Don Jones, vice president of business development for the health and life sciences division of wireless-technology company Qualcomm: “It’s only through wireless connectivity that you’ll create that opportunity.”
Proteus is just one of a growing number of startup companies with monitoring technologies that address conditions from congestive heart failure (Corventis, CardioMems) to asthma (PHT, Cambridge Consultants) to diabetes (DexCom, Airstrip).
Monitoring devices have the potential to act as the human equivalent of a car’s instrument panel: the more gauges and indicator lights there are, the more warning you have that something is off kilter, so you can take the steps that forestall engine breakdowns and emergency roadside assistance. Continuous glucose meters allow diabetics to check their blood-sugar levels by consulting a display on their smart phones the way drivers can glance at the gas gauge. Sensors that monitor sleep apnea—which increases the risk of heart disease and stroke—are like an air-filter warning light. A peak-flow meter that attaches to an inhaler, transmitting data about an asthma patient’s exhalation, is analogous to an exhaust-system indicator.
Hospitals are especially interested in technology that detects warning signs of heart failure. Most cases of congestive heart failure are entirely manageable with the right medications and lifestyle changes (exercise more, eat less salt), yet more than a third of patients released from the hospital after treatment for this condition are readmitted within 12 months. A single readmission can cost $10,000 to $40,000 or more. And starting in 2012, Medicare and Medicaid will stop reimbursing hospitals for heart-failure readmissions that occur within 60 days. The policy change has prompted some hospitals to look harder at preventive measures such as wireless health monitoring. After all, their survival could depend on it.
Yet many bureaucratic barriers to implementing such technologies still remain. The FDA has been slow to approve most wireless health devices because of concerns about privacy, security, and data loss. Hospitals and insurers are hesitant to adopt them because they’re concerned about increased short-term costs.
Physicians, meanwhile, are concerned about data quality, liability, and expense. “There’s not much incentive for providers to take in monitored data,” says Ronald Dixon, a physician and director of the virtual practice project at Massachusetts General Hospital. “The monitoring service gets payment, but there’s no incentive for me to pay attention to it. I want to help the patient, but [in the current system] I’m not getting paid to do so.”
In the past, new medical technologies were likely to be deemed worthwhile if they improved care. That may no longer be true unless they significantly decrease costs as well. Even if wireless monitoring produces some savings down the road, as it almost surely will, hospitals and insurers may not feel it justifies the up-front expense.
“All of the innovations around monitoring have to be at worst cost-neutral, and at best cost-effective,” Dixon says. “They’re only going to be taken up by a relatively small portion of the population if they’re expensive.”
The managed-care giants are the big wild card when it comes to how widely these technologies will be adopted. Medco, the health-care company and pharmacy benefits giant, wouldn’t comment on whether it had any interest in such an approach. Others are cautiously entering the game. United Healthcare, for example, recently approved reimbursement for a device made by Watermark Medical that can detect obstructive sleep apnea in a patient’s own bedroom, eliminating the need to spend the night in a sleep lab.
Kaiser Permanente, headquartered in Oakland, California, operates a more integrated system of hospitals and health-care plans. Because spending on prevention saves its hospitals money, the company tends to be more forward-thinking. It is already studying how monitoring technologies—including Proteus’s smart pills—might be best put to use. “We’ve been doing experiments with various prototypes to see how it would integrate with our system,” says Faye Sahai, Kaiser’s executive director of innovation and advanced technology.
Wireless technologies could ensure that doctors are seeing the most urgent patients first, but they could also impose time-consuming new tasks. Those range from watching pulse and respiration rates to checking blood-glucose levels to monitoring the amount of fluid in a patient with chronic heart failure. Even with smart-phone access to all a patient’s data, doctors don’t have much time to sort through it. Any work flow incorporating such technologies will require an integrated alert system that won’t intrude on doctors’ already crammed days.
A few companies have built monitoring centers that review patient data, interpret it, and send it to the prescribing physician. But such setups are still relatively rare, and there’s a huge opening for businesses to compile and distill what some people in the field refer to as the “data tsunami.” “At the end of the day, it’s going to be smart intermediaries that package the information and put it in the physician’s hands, and then you have to rely on the physician to do what’s appropriate,” says Qualcomm’s Don Jones.
Ultimately, the infrastructure for wireless health monitoring is more likely to be built in Europe and even in developing countries long before it happens in the United States. Until there’s a change in the fee-for-service model used by most U.S. insurers—until there’s a financial incentive for prevention, and a system that compensates physicians for time spent keeping their patients out of the hospital—health monitoring technologies will remain a niche market.
These materials were meant to revolutionize the solar industry. Why hasn’t it happened?
Perovskites are promising, but real-world conditions have held them back.
Why China is still obsessed with disinfecting everything
Most public health bodies dealing with covid have long since moved on from the idea of surface transmission. China’s didn’t—and that helps it control the narrative about the disease’s origins and danger.
Anti-aging drugs are being tested as a way to treat covid
Drugs that rejuvenate our immune systems and make us biologically younger could help protect us from the disease’s worst effects.
A quick guide to the most important AI law you’ve never heard of
The European Union is planning new legislation aimed at curbing the worst harms associated with artificial intelligence.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.